Phase II ftorafur therapy in previously treated squamous cell cancers of the head and neck.
A prospective study was carried out to determine the effectiveness and tolerance of ftorafur (2.25 g/m2 daily for 5 days, repeated every 4 weeks) in previously treated patients with advanced squamous cell cancers of the head and neck. Seventeen patients were entered in the study; 15 were evaluable for drug toxicity, and 14 were evaluable for response. Three patients had mild nausea, three had mild-to-moderate lethargy, two had nonspecific generalized weakness, and two had severe stomatitis. Of 15 patients three experienced leukopenia (causing death in one) and four had thrombocytopenia (life-threatening to one). Response to treatment included: progressive disease (nine patients), stable disease (four), and complete response (one with no previous radiotherapy or chemotherapy).
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D005641:Tegafur / Q000627:therapeutic use*
D005641:Tegafur; D005472:Fluorouracil